120 related articles for article (PubMed ID: 36958671)
1. Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.
Bianzano S; Henrich A; Herich L; Kalsch B; Sarubbi D; Seitz F; Forst T
Metabolism; 2023 Jun; 143():155550. PubMed ID: 36958671
[TBL] [Abstract][Full Text] [Related]
2. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Jungnik A; Arrubla Martinez J; Plum-Mörschel L; Kapitza C; Lamers D; Thamer C; Schölch C; Desch M; Hennige AM
Diabetes Obes Metab; 2023 Apr; 25(4):1011-1023. PubMed ID: 36527386
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome.
Miller JL; Lacroix A; Bird LM; Shoemaker AH; Haqq A; Deal CL; Clark KA; Ames MH; Suico JG; de la Peña A; Fortier C
J Clin Endocrinol Metab; 2022 May; 107(6):e2373-e2380. PubMed ID: 35213714
[TBL] [Abstract][Full Text] [Related]
4. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.
Moschetti V; Desch M; Goetz S; Liesenfeld KH; Rosenbrock H; Kammerer KP; Wunderlich G; Wind S
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):239-249. PubMed ID: 29076028
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L
BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.
Allas S; Delale T; Ngo N; Julien M; Sahakian P; Ritter J; Abribat T; van der Lely AJ
Diabetes Obes Metab; 2016 Sep; 18(9):868-74. PubMed ID: 27063928
[TBL] [Abstract][Full Text] [Related]
8. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
Yazawa R; Ishida M; Balavarca Y; Hennige AM
Diabetes Obes Metab; 2023 Jul; 25(7):1973-1984. PubMed ID: 36974349
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
12. Overweight and obesity in type 1 diabetes is not associated with higher ghrelin concentrations.
Özcan B; Delhanty PJD; Huisman M; Visser JA; Neggers SJ; van der Lely AJ
Diabetol Metab Syndr; 2021 Jul; 13(1):79. PubMed ID: 34294136
[TBL] [Abstract][Full Text] [Related]
13. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
14. Ghrelin O-acyltransferase knockout mice show resistance to obesity when fed high-sucrose diet.
Kouno T; Akiyama N; Ito T; Okuda T; Nanchi I; Notoya M; Oka S; Yukioka H
J Endocrinol; 2016 Feb; 228(2):115-25. PubMed ID: 26645250
[TBL] [Abstract][Full Text] [Related]
15. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
17. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
Guérard N; Morand O; Dingemanse J
Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
[TBL] [Abstract][Full Text] [Related]
18. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Bianzano S; Nordaby M; Plum-Mörschel L; Peil B; Heise T
Diabetes Obes Metab; 2023 Mar; 25(3):832-843. PubMed ID: 36478142
[TBL] [Abstract][Full Text] [Related]
20. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults.
Parnell JA; Reimer RA
Am J Clin Nutr; 2009 Jun; 89(6):1751-9. PubMed ID: 19386741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
